NEW YORK (GenomeWeb) – Luminex said today that the US Food and Drug Administration has given 510(k) clearance for the firm's Aries C. difficile assay — a moderate complexity, sample-to-answer test for rapid detection of Clostridium difficile, which has become a common microbial cause of healthcare-associated infections in US hospitals.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine writes that proteomics might be better poised than genomics to say when someone is falling ill.

Bloomberg profiles IndieBio, a startup incubator for the life sciences.

In an editorial, Nature calls for the end to the exploitation of foreign postdocs.

In Nucleic Acids Research this week: collection of epigenome-wide association study data, updated BloodSpot database, and more.